Cutaneous T Cell Lymphoma Clinical Trial
Official title:
A Study of Molecular Subtyping-based Therapeutic Strategies for Cutaneous T-cell Lymphoma
Cutaneous T-cell lymphoma (CTCL) is a group of diseases resulting from clonal hyperplasia of memory T cells in the skin. The increasing incidence and high treatment costs have posed significant challenges to public health and the economy. Current treatment guidelines only provide partial control, leading to varying remission times and recurrence rates. This study aims to use molecular subtyping and immunohistochemistry to guide treatment selection for CTCL patients, aiming to prolong clinical benefit, improve treatment safety, and reduce economic burden.
The study focuses on the impact of treatment strategy selection based on molecular typing for patients with cutaneous T-cell lymphoma. The study aims to evaluate the effect on clinical benefit time and long-term prognosis, assess the safety of the treatment strategy, and explore the interaction between baseline factors and treatment regimens. This research could potentially provide valuable evidence for precision treatment in the context of cutaneous T-cell lymphoma. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT02546440 -
Study on Therapy With Dimethylfumarate (DMF) in Patients With Cutaneous T Cell Lymphoma (CTCL)
|
Phase 2 | |
| Recruiting |
NCT04014374 -
Post-authorization Safety Study of Allogeneic Hematopoietic Stem Cell Transplantation in Patients Treated With Mogamulizumab
|
||
| Recruiting |
NCT03340155 -
Mechanisms of Action of Photo(Chemo)Therapy in Skin Diseases
|
N/A | |
| Active, not recruiting |
NCT01460914 -
Outcomes of Cutaneous T-Cell Lymphoma and Graft-Versus-Host Disease With Extracorporeal Photopheresis Treatment
|
||
| Completed |
NCT04955340 -
A Phase 1, Open-label Study of the Absorption, Metabolism, Excretion of [14C]-Resminostat
|
Phase 1 | |
| Recruiting |
NCT02539472 -
Early Diagnosis of Mycosis Fungoides
|
N/A | |
| Recruiting |
NCT05680558 -
Photopheresis in Early-stage Mycosis Fungoides
|
Phase 2 | |
| Recruiting |
NCT01132989 -
Open-label Pilot Study of Lenalidomide (Revlimid) as Adjuvant Treatment for Refractory Cutaneous T Cell Lymphoma
|
Phase 2 | |
| Recruiting |
NCT05414500 -
Mogamulizumab and Brentuximab Vedotin in CTCL and Mycosis Fungoides
|
Phase 1 | |
| Terminated |
NCT01663571 -
STAT3 in T Cells: At The Crossroads of Inflammation and Cancer
|
||
| Active, not recruiting |
NCT02192021 -
Micro Needle Array-Doxorubicin (MNA-D) in Patients With Cutaneous T-cell Lymphoma (CTCL)
|
Phase 1 | |
| Recruiting |
NCT05781386 -
A Phase I Trial of SIM1811-03 in Subjects With Advanced Tumors
|
Phase 1 | |
| Active, not recruiting |
NCT02576496 -
Study of Tinostamustine, First-in-Class Alkylating HDACi Fusion Molecule, in Relapsed/Refractory Hematologic Malignancies
|
Phase 1 | |
| Active, not recruiting |
NCT03775525 -
Study Evaluating GZ17-6.02 in Patients With Advanced Solid Tumors or in Combination With Capecitabine in Metastatic Hormone Receptor Positive Breast Cancer
|
Phase 1 | |
| Withdrawn |
NCT03235869 -
Radiation Therapy Plus Durvalumab for Tumor-Stage Cutaneous T-Cell Lymphoma
|
Early Phase 1 | |
| Active, not recruiting |
NCT01396070 -
Pilot Study of Brentuximab Vedotin (SGN-35) in Patients With MF With Variable CD30 Expression Level
|
N/A | |
| Completed |
NCT01198665 -
RAD001 Combined With CHOP in Newly Diagnosed Peripheral T-cell Lymphomas
|
Phase 1/Phase 2 | |
| Recruiting |
NCT03932279 -
Characterization of the Microbiome in Cutaneous T Cell Lymphoma
|
||
| Not yet recruiting |
NCT05728879 -
Characterization of the Microbiome in Cutaneous T Cell Lymphoma Skin Lesions Before and After Use of APR-TD011® (RLF-TD011®) Spray Solution
|
Early Phase 1 | |
| Not yet recruiting |
NCT06113081 -
Real World Experience With Mogamulizumab in the Treatment of Cutaneous T-cell Lymphoma
|